National ANTIBIOTIC RESISTANCE Portal

Home • Editorials

A Decrease font size. A Reset font size. A Increase font size.

Editorials

17 June 2025

Antibiotic therapy, everyone’s business

Editorials, News

The rise in antimicrobial resistance is an increasingly critical public health issue worldwide. It requires the mobilisation of various public and private players in the healthcare sector. Among them, pharmaceutical companies such as Pfizer have been involved for years in the fight again ...

28 May 2025

Social science perspectives on understanding and overcoming antibiotic dependence

Editorials

It is now common knowledge that antimicrobial resistance (AMR) is a social problem that must not only be studied as a biomedical challenge, but for which other factors - i.e. sociological, economic, political and cultural determinants - must be taken into account. Most research into soci ...

19 February 2025

Europe united in the fight against antibiotic resistance.

Editorials

Antibiotic resistance (AMR) is now one of the major public health challenges worldwide. Antibiotics, which are essential to modern medicine, are used to treat and prevent many infections, particularly during surgery, transplants and chemotherapy.

20 September 2024

Attempting to improve access to “forgotten” antibiotics in Europe

Reliable access to antibiotics is an essential part of a functioning modern healthcare system, meaning that infections can be treated and advanced procedures like chemotherapy and organ transplants can be performed at acceptable risk levels.

1 July 2024

Diagnostic tests – an asset for the proper use of antibiotics

Editorials
France
Antimicrobial Resistance, diagnostic test, Editorial, public-private partnership, resistance

Since the COVID-19 pandemic, diagnostic tests such as PCR and rapid tests have become part of the public lexicon. Rapid diagnosis also plays a crucial role in identifying and treating microbial infections, and in slowing down antimicrobial resistance (AMR).

15 February 2024

Transferable exclusivity extensions to fund research into antibiotic resistance

Editorials
France
Antimicrobial Resistance, Editorial, Funding, Industrial partner, resistance

While the need for new antibiotics is urgent and should naturally attract investors, there is too little innovation and R&D in the field of antibiotic resistance. We are facing what is known as a market failure, the main reason for which is linked to the need to preserve their value for publ ...

14 September 2023

Antimicrobial Resistance: The Silent Pandemic

Editorials
France
Antimicrobial Resistance, Editorial, Industrial partner

Antimicrobial resistance (AMR), a ‘silent’ or ‘overlooked’ pandemic, 1,2 is classed as a threat to global health and development by the World Health Organization (WHO). If left unchecked, it could cause 10 million deaths per year by 2050,3 cost the global economy US ...

2 June 2023

Editorial by Jean-Yves Madec

Editorials
France
Anses, Antimicrobial Resistance, OneHealth

Antibiotic resistance: One Health or not One Health?

5 May 2023

Editorial by Frédéric Peyrane and Florence Séjourné

Editorials

2023: a pivotal year for innovation in antibiotic resistance?

15 June 2022

Editorial by Isabelle TONGIO

Editorials, News

The emergence and development of antibiotic resistance is mainly linked to the inappropriate use of antibiotics. In vitro diagnostic systems and tests detect and identify pathogens and assess their sensitivity to certain antibiotics, that is why they have a key role in ...

Cookies

This website uses cookies to improve your experience when browsing the website. Of these cookies, the cookies categorized as necessary are stored on your browser as they are essential for the functioning of basic website functionality. We also use third-party cookies which help us analyze and understand how you use this website. These cookies will only be stored in your browser with your consent. You also have the option of deactivating these cookies. But disabling some of these cookies may have an effect on your browsing experience.

Necessary

Always Enabled

Les cookies nécessaires sont absolument essentiels au bon fonctionnement du site Web. Cette catégorie comprend uniquement les cookies qui garantissent les fonctionnalités de base et les fonctionnalités de sécurité du site Web. Ces cookies ne stockent aucune information personnelle.

Cookie	Duration	Description
cookielawinfo-checkbox-necessary	11 mois	This cookie is set by the GDPR Cookie Consent plugin. Cookies are used to store user consent for cookies in the "Necessary" category.
cookielawinfo-checkbox-non-necessary	11 mois	This cookie is set by the GDPR Cookie Consent plugin. Cookies are used to store user consent for cookies in the "Not necessary" category.
cookielawinfo-checkbox-stats	1an	This cookie is set by the GDPR Cookie Consent plugin. The purpose of this cookie is to check whether or not the user has given his consent to the use of cookies in the “Statistics” category.
viewed_cookie_policy	11 mois	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not the user has consented to the use of cookies. It does not store any personal data.

Performance

Ils servent à collecter les informations sur l’utilisation du site, par exemple les pages que vous visitez, ou les messages d’erreur rencontrés. Ces cookies ne collectent aucune information permettant de vous identifier – toute l’information collectée est anonyme et n’est utilisée que dans le but d’améliorer le fonctionnement de notre site.

Cookie	Type	Duration	Description
_GPSLSC	0	4 minutes	This cookie is associated with a page speed script to improve the speed of the web page.

Statistics

Tous les cookies qui peuvent ne pas être particulièrement nécessaires au fonctionnement du site Web et qui sont utilisés spécifiquement pour collecter des données personnelles des utilisateurs via des analyses, des publicités et d’autres contenus intégrés sont appelés cookies non nécessaires. Il est obligatoire d’obtenir le consentement de l’utilisateur avant d’exécuter ces cookies sur votre site Web.